Decoy Therapeutics Inc.
Datakwaliteit: 83%
DCOY
Nasdaq
Manufacturing
Chemicals
€ 6,00
▲
€ 0,37
(6,57%)
Marktkapitalisatie: 3,19 M
Prijs
€ 6,00
Marktkapitalisatie
3,19 M
Dagbereik
€ 5,63 — € 6,05
52-Weeksbereik
€ 5,40 — € 415,80
Volume
13.340
Openen € 5,80
50D / 200D Gem.
€ 8,14
26,27% below
50D / 200D Gem.
€ 48,08
87,52% below
Quick Summary
Belangrijkste Punten
Negative free cash flow of -4,83 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-732,43%
Onder sectorgemiddelde (-53,47%)
ROIC-266,10%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current RatioN/A
Interest CoverageN/A
Waardering
PE (TTM)
-0,25
Boven sectorgemiddelde (-1,47)
P/B Ratio0,75
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -0,3 | -1,5 |
| P/B | 0,8 | 1,6 |
| ROE % | -732,4 | -53,5 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -12,52 M |
| ROE | -732,43% | ROA | -334,28% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -4,83 M |
| ROIC | -266,10% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | N/A |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | N/A | Tangible Book Value | 4,25 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0,25 | Forward P/E | N/A |
| P/B Ratio | 0,75 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -151,22% | ||
| Market Cap | 3,19 M | Enterprise Value | -1,62 M |
| Per Share | |||
| EPS (Diluted TTM) | -129,10 | Revenue / Share | N/A |
| FCF / Share | -9,07 | OCF / Share | -9,07 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 38,56% |
| SBC-Adj. FCF | -4,97 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 0,0 | 1,84 M |
| Net Income | -12,52 M | -5,58 M | -12,54 M | -31,61 M | -12,77 M |
| EPS (Diluted) | -129,10 | -5,79 | -3,84 | -14,88 | -0,31 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -12,61 M | -5,73 M | -12,89 M | -31,84 M | -12,81 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 368.170,0 | 770.027,0 | 7,17 M | 15,84 M | 8,55 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 7.151,0 | 4.424,0 | 10.051,0 | 6.677,0 | 19.183,0 |
| Interest Expense | — | — | — | — | — |
| Income Tax | 0,0 | — | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 11,06 M | 3,02 M | 6,59 M | 14,65 M | 40,83 M |
| Total Liabilities | 5,17 M | 1,51 M | 1,30 M | 4,27 M | 2,11 M |
| Shareholders' Equity | 5,89 M | 1,51 M | 5,29 M | 10,38 M | 38,72 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 10,71 M | 2,43 M | 5,90 M | 12,11 M | 29,21 M |
| Current Assets | 10,99 M | 2,99 M | 6,52 M | 14,52 M | 30,16 M |
| Current Liabilities | 5,17 M | — | — | — | — |
{"event":"ticker_viewed","properties":{"ticker":"DCOY","listing_kind":"stock","pathname":"/stocks/dcoy","exchange":"Nasdaq","country":"US"}}